Scope
AAO guidance for adult primary open-angle glaucoma suspects centres on documenting optic-nerve structure and visual function, estimating future risk and deciding between observation and pressure lowering. A suspicious finding is not automatically established glaucoma. Long-term surveillance remains necessary even when treatment is deferred, and treatment targets must reflect the individual risk of visual disability.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Confirm the suspect category and assess individual risk
- A glaucoma suspect has an open anterior chamber angle with raised intraocular pressure, suspicious optic-nerve or retinal nerve-fibre findings, or a suspicious visual field without meeting established glaucoma criteria. Angle closure and known secondary open-angle mechanisms are outside this category. [1]
- Assess risk using pressure, age, family history, myopia, corneal thickness, disc haemorrhage and structural or field findings. The treatment decision should also account for life expectancy, prognosis, preferences and whether long-term treatment is feasible. [1]
- Do not rely on pressure alone: glaucoma suspects without ocular hypertension require assessment of both optic-nerve structure and function. Initial evaluation may need several visits and repeated measurements. [1]
Establish a reliable baseline
- Review ocular trauma, surgery, family glaucoma severity, systemic disease and medications, including corticosteroids and antihypertensives. Previous corneal refractive surgery can produce falsely low pressure readings because the cornea is thinner. [1]
- Measure pressure in each eye, preferably with Goldmann applanation, before gonioscopy or pupil dilation. Record timing when useful and obtain measurements on different occasions if needed to understand fluctuations. [1]
- Perform and document gonioscopy to establish an open angle and exclude angle closure or secondary causes such as recession, pigment dispersion, pseudoexfoliation and neovascularisation. [1]
- Measure central corneal thickness to interpret pressure and stratify risk. Thin and thick corneas can bias applanation readings, but there is no generally accepted correction formula; do not treat a numerical correction as a true individual pressure. [1]
- Document optic-disc and retinal nerve-fibre appearance clinically and with imaging. Photographs and computer imaging are complementary; examine the dilated fundus where feasible for alternative explanations of nerve or field abnormalities. [1]
- Use standard automated perimetry and repeat a newly detected glaucomatous field defect using the same testing strategy before accepting progression. A central 10-2 test may reveal defects missed by wider fields. [1]
- Interpret OCT with scan quality, clinical examination and other tests. An abnormal colour-coded result is not itself glaucoma; myopia and the reference database can cause apparent abnormality. Structural and functional assessments both remain necessary. [1]
- Consider other optic neuropathies or retinal disease when findings are atypical. Pallor exceeding cupping or field loss aligned with the vertical meridian suggests a nonglaucomatous disorder. [1]
Treat higher risk or documented conversion
- Offer glaucoma treatment when characteristic optic-nerve deterioration establishes conversion to POAG. Confirm a new glaucomatous field defect on repeat testing. Very high pressure likely to damage the nerve or a high-risk combination may justify treatment before conversion. [1]
- When treatment is chosen for a suspect, a reasonable initial target is about 20% below the mean of several baseline pressure measurements. Markedly high baseline pressure may need a larger reduction; reassess target pressure at each visit rather than assuming one fixed goal. [1]
- Discuss observation versus pressure lowering with the patient. Risk calculators can assist estimates of conversion from ocular hypertension, but treatment remains an individual decision integrating examination, prognosis, benefits and harms. [1]
Choose an effective, feasible pressure-lowering approach
- For a treated glaucoma suspect, consider laser trabeculoplasty or medication. Laser trabeculoplasty can be first-line for ocular hypertension; trial findings in ocular hypertension do not directly apply to suspects without raised pressure. [1]
- Prostaglandin analogues are often the initial medical option, unless contraindications, cost, adverse effects, intolerance or patient preference preclude them. Select a regimen with attention to ocular and systemic toxicity and interactions. [1]
- If medication does not lower pressure adequately, switch monotherapy or add treatment. Assess response against several baseline measurements in the same eye; a short monocular trial is not a reliable prediction of long-term efficacy. [1]
- At each visit, review adherence, technique, adverse effects, dose timing and practical barriers. Written instructions, reminders and teaching the patient or helper to instil drops can help. Explain eyelid closure or nasolacrimal occlusion to reduce systemic absorption. [1]
- Pregnancy and breastfeeding require an interdisciplinary risk-benefit assessment; discuss punctal occlusion. Do not use brimonidine in a breastfeeding mother because it can cause infant apnoea and somnolence. [1]
Continue risk-based surveillance
- Observed suspects should generally be reviewed at least every 12–24 months, with shorter intervals for multiple risks. Treated suspects may need closer visits until pressure is controlled, then six-monthly or annual review. Tailor structural imaging and field testing to risk. [1]
- Repeat gonioscopy for suspected angle closure, chamber shallowing, angle abnormalities or unexplained pressure change. Adjust therapy for failure to achieve target, intolerance, nonadherence or new contraindications; conversion to POAG needs the established-glaucoma pathway. [1]
Limitations and use
- This summary concerns adults with primary open-angle glaucoma suspicion or ocular hypertension, not paediatric, angle-closure or established secondary glaucoma.
- Medication selection requires the full contraindication and adverse-effect review. This summary does not provide drop doses, surgical technique or a complete pregnancy treatment protocol.
- Follow-up and target-pressure figures are starting points, not universal safety thresholds. Normal pressure or a single reassuring test does not replace longitudinal structure and function assessment.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Primary open-angle glaucoma suspect
Selected recommendation material consulted
Publication details
- Issuing organisation
- AAO
- First published
- 9 February 2026
- Resource type
- Preferred Practice Pattern guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.